by EpicentRx | Sep 1, 2023 | Conferences
June 2023; Chicago, Illinois Poster: RRX-001 Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001 TGF-ß Trap (NCT04673942) Poster: RRX-001, KEVLARx: A phase 2b, multi-institutional, randomized,...